Survodutide is an investigational, once-weekly injectable peptide built on the glucagon hormone backbone that activates both the glucagon and GLP-1 receptors together, a dual-agonist design different from single-target drugs like semaglutide. In its largest completed trial it produced roughly 12 to 13 percent weight loss over 76 weeks, a real number, though most of the higher figures quoted for it online (16 to 19 percent) come from secondary statistical analyses rather than the trial’s primary result. It also has a promising liver-disease signal and holds Breakthrough Therapy designation for that use. It is not approved anywhere, for anything, and its phase 3 rate of stopping due to side effects, roughly one in four people, is several times higher than approved drugs in its class.
Ask about Survodutide
Research snapshot
| Category | Current information |
|---|---|
| Peptide category | Dual glucagon (GCGR) / GLP-1 receptor agonist, built on the glucagon backbone |
| Primary research interest | Chronic weight management; MASH (liver disease) and fibrosis; type 2 diabetes |
| Highest available evidence | Tier 1 – published phase 3 human trials (NEJM, Nature Medicine) |
| Human research available | Yes, extensive – phase 2 and phase 3 across obesity, MASH, and type 2 diabetes; cardiovascular outcomes trial completed but unpublished |
| Development status | In clinical development; Boehringer Ingelheim (licensed from Zealand Pharma) |
| Regulatory status | Not approved anywhere, for any use; FDA Breakthrough Therapy and Fast Track (MASH only), EMA PRIME |
Technical identity
| Technical property | Information |
|---|---|
| Primary name | Survodutide |
| Alternative names | BI 456906 (code name), survodutide acetate |
| Peptide sequence | H-Ac4c-QGTFTSDYSKYLDERAAKDFI-X-WLESA-NH2 (Ac4c = 1-aminocyclobutane-1-carboxylic acid at position 2; X = glycine-serine linker at position 24 carrying a C18 diacid; C-terminally amidated). Linker notation approximate, per a truncated supplier listing. |
| Amino-acid length | 29 residues |
| Molecular formula | C192H289N47O61 – from a chemical supplier data sheet only, not confirmed against a peer-reviewed or regulatory source |
| Molecular weight | 4231.7 g/mol – from a chemical supplier data sheet only, not confirmed against a peer-reviewed or regulatory source |
| CAS Registry Number | 2805997-46-8 – from vendor catalogues; salt-form assignments in those catalogues are not reliable |
| Chemical modifications | Ac4c substitution (DPP-4 resistance), C18 diacid via Gly-Ser linker (albumin binding), C-terminal amidation |
| Peptide class | Glucagon-backbone dual GCGR/GLP-1R agonist |
| Primary biological target | Glucagon receptor and GLP-1 receptor (approx. 8-fold GLP-1R bias in 100% human plasma) |
| Developer or originator | Boehringer Ingelheim, licensed from Zealand Pharma |
| Development status | Phase 3 (obesity, liver disease); not approved anywhere |
What it is
Survodutide is a synthetic 29 amino acid peptide built on the human glucagon backbone, not the GLP-1 backbone. It is a dual agonist of the glucagon and GLP-1 receptors, engineered to reproduce what the gut peptide oxyntomodulin does weakly. Boehringer Ingelheim develops it as BI 456906, licensed from Zealand Pharma. It has no GIP receptor activity, is not a triple agonist, and is approved nowhere.
Calling it a GLP-1 analogue, which happens constantly, gets the molecule backwards. Zimmermann and colleagues, in the 2022 discovery paper, document three modifications to the glucagon sequence: the non coded residue Ac4c, 1-aminocyclobutane-1-carboxylic acid, at position 2, blocking dipeptidyl peptidase-4 cleavage; a glycine serine linker at position 24 carrying a C18 diacid, which binds albumin and gives once weekly dosing; and C terminal amidation. It was picked from a screen of nineteen dual agonists, alongside BI 456908 and BI 456897, which are different molecules.
Mechanism, including the part nobody explains
Two potency figures circulate and both are correct, because they are different assays. Zimmermann measured potency in CHO-K1 cells at 0.33 nM for the GLP-1 receptor and 0.52 nM for the glucagon receptor, near balanced and about ten fold weaker than native GLP-1 at 60 pM and glucagon at 20 pM. In 100 percent human plasma the same molecule gave 1.0 nM and 8.3 nM. That second ratio is the source of the sponsor statement in Nature Medicine 2026, verbatim: survodutide has an eight-fold greater activation of the human GLP-1R than the glucagon receptor in vitro. The drug circulates bound to albumin, so the plasma figure is the relevant one.
Glucagon is the counter-regulatory hormone to insulin, so agonising its receptor in an insulin resistant person looks like adding to the problem. That resolves empirically. In diet induced obese mice, Zimmermann ran survodutide, semaglutide and a glucagon receptor only agonist at weight matched doses: the glucagon only agonist raised blood glucose, the other two lowered it. In the phase 2 type 2 diabetes trial, HbA1c fell by up to 18.72 mmol/mol, which is 1.71 percent, at 1.8 mg weekly, with plasma alanine and glucagon falling as target engagement.
The cleanest mechanistic statement available is a 2026 Molecular Metabolism paper. It found the glucagon receptor barely detectable in the area postrema and arcuate nucleus at single cell level while the GLP-1 receptor is expressed there, then ran the control, verbatim: a long-acting GCGR agonist did not induce neuronal activation in satiety-mediating regions, nor reduced food intake but showed reduction in body weight. Appetite is the GLP-1 arm. Weight loss beyond appetite is the glucagon arm. In mice, survodutide suppressed food intake less than semaglutide and lost more weight.
Potential benefits and research applications
Weight loss via dual glucagon and GLP-1 receptor activation
What is being investigated: whether combining glucagon receptor activation, which raises energy expenditure in animal models, with GLP-1 receptor activation, which suppresses appetite, produces more weight loss than either alone. How the effect might occur: in mice, survodutide suppressed food intake less than semaglutide but lost more weight, consistent with an added energy-expenditure component. Evidence: the phase 3 SYNCHRONIZE-1 trial showed 12.2 to 13.0 percent weight loss at 76 weeks on its primary, most conservative analysis. Strength: has been shown in a large, well-controlled human trial. Limitation: whether the proposed energy-expenditure mechanism actually operates in humans has never been directly measured; a dedicated trial to test it will not report until 2027.
Liver disease (MASH and fibrosis)
What is being investigated: whether survodutide can improve or resolve metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis. How the effect might occur: partly through weight loss and partly through a liver-specific pathway, since a mediation analysis found only about a third of the fibrosis benefit was explained by weight loss alone. Evidence: the phase 2 MASH trial showed 47 to 62 percent achieving MASH improvement against 14 percent on placebo, with the FDA granting Breakthrough Therapy designation for this specific use in October 2024. Strength: has been shown in a randomised, biopsy-confirmed phase 2 trial. Limitation: the dose-response was not a clean upward curve, the higher dose actually performed worse than the middle one, and the only completed phase 3 liver trial did not use a biopsy endpoint at all.
Type 2 diabetes and glycemic control
What is being investigated: HbA1c reduction, addressing the theoretical concern that adding glucagon receptor activity might worsen blood sugar. How the effect might occur: net glucose-lowering despite glucagon receptor engagement, because the paired GLP-1 activity outweighs it. Evidence: a phase 2 trial found HbA1c fell by up to 1.71 percentage points at 16 weeks. Strength: has been shown to lower HbA1c in a controlled human trial, resolving the theoretical glucose concern empirically. Limitation: the diabetes-specific dose range tested was well below what is being carried into obesity and liver-disease trials, so it is not the population the drug is being developed for.
What the human trials found
No dose of survodutide has been established as safe or effective, because the compound is not approved in any country and has no label anywhere. What follows is a record of what named trials administered, in the past tense, and nothing in it is a regimen. This site does not reproduce circulating vendor dosage figures for survodutide – see the section below for why.
| Trial | Route | Amount reported | Frequency reported | Reported duration | Evidence category |
|---|---|---|---|---|---|
| SYNCHRONIZE-1 (obesity, phase 3) | Subcutaneous | Dose adjusted up to 3.6 mg or 6.0 mg | Once weekly | 76 weeks | Published human clinical trial (NEJM) |
| SYNCHRONIZE-MASLD (liver, phase 3) | Subcutaneous | 6.0 mg (2.4 mg lowest permitted maintenance) | Once weekly | 48 weeks | Published human clinical trial (Nature Medicine) |
| Phase 2 obesity (NCT04667377) | Subcutaneous | 0.6, 2.4, 3.6, or 4.8 mg | Once weekly | 46 weeks | Published human clinical trial (Lancet D&E) |
| Phase 2 MASH (NCT04771273) | Subcutaneous | 2.4, 4.8, or 6.0 mg | Once weekly | 48 weeks | Published human clinical trial (NEJM) |
| Phase 2 type 2 diabetes (NCT04153929) | Subcutaneous | Up to 0.3–2.7 mg weekly or 1.2–1.8 mg twice weekly | Weekly or twice weekly | 16 weeks | Published human clinical trial (Diabetologia) |
The phase 2 obesity trial, NCT04667377, treated 386 adults at 0.6, 2.4, 3.6 or 4.8 mg weekly or placebo for 46 weeks, 20 of escalation and 26 of maintenance. By planned treatment, the primary analysis, weight changed minus 6.2, minus 12.5, minus 13.2 and minus 14.9 percent against minus 2.8 percent placebo. Completion was 60.4 percent.
SYNCHRONIZE-1, NCT06066515, randomised 725 adults with obesity and without diabetes to a dose adjusted up to 3.6 or 6.0 mg, or placebo, for 76 weeks. On the prespecified primary analysis, the treatment regimen estimand, mean weight change was minus 12.2 percent (95 percent confidence interval minus 13.6 to minus 10.8) at 3.6 mg, minus 13.0 percent (minus 14.4 to minus 11.6) at 6.0 mg and minus 5.4 percent (minus 6.9 to minus 4.0) on placebo, with at least 5 percent lost by 72.6, 71.9 and 46.3 percent.
SYNCHRONIZE-MASLD, NCT06309992, treated 216 people at 6.0 mg or placebo two to one for 48 weeks, co-primary endpoints liver fat responder rate and weight. On the treatment regimen estimand, 68.5 against 28.6 percent achieved at least a 30 percent liver fat reduction, and weight fell 8.7 against 1.4 percent. Both endpoints were met on both estimands. A Nature Medicine author correction appeared on 25 August 2026 and its content is not indexed, so figures from that paper need checking against it.
Why the number you have read is a secondary analysis
Every circulating survodutide headline is real, and every one is a secondary analysis. The 16.6 percent figure is the efficacy estimand at 6.0 mg in SYNCHRONIZE-1, where the prespecified primary is minus 13.0 percent against minus 5.4 percent placebo. The 18.7 percent figure is the actual treatment sensitivity analysis of the 4.8 mg phase 2 arm, where the primary is minus 14.9 percent.
The tell is the placebo. A treatment regimen estimand includes what happened after people stopped, escalated slowly or took prohibited weight medication. An efficacy estimand models the trial as if everyone had adhered and nobody used those medications, which lifts the drug arm and drops the placebo arm. So placebo moves in the opposite direction to the drug: 5.4 percent becomes 3.2 in SYNCHRONIZE-1, and 2.8 becomes 2.3 in phase 2. The placebo adjusted difference nearly doubles, from 7.6 percentage points to 13.4. Find the placebo figure first, ask which way it moved, and you can audit any weight loss claim.
The MASH result, as published
The phase 2 MASH trial, NCT04771273, randomised 293 treated adults with biopsy confirmed MASH and F1 to F3 fibrosis to 2.4, 4.8 or 6.0 mg or placebo for 48 weeks, including 24 weeks of what the authors call rapid escalation. In the New England Journal of Medicine report, MASH improvement without worsening of fibrosis occurred in 47, 62 and 43 percent against 14 percent placebo, p less than 0.001 for a quadratic dose response as best fitting model. Fibrosis improvement of at least one stage occurred in 34, 36 and 34 percent against 22 percent, with no p value, no interval and no claim of significance, and the conclusion names only the primary endpoint.
The 83 percent and 64.5 percent figures are not that result. They come from the sponsor release of 7 June 2024, a less conservative analysis of the same trial, and the giveaway is again the placebo rates: 18.2 percent for MASH and 25.9 percent for fibrosis in F2 to F3, against 14 and 22 percent in the publication. The dose response is also non monotonic. Response peaked at 4.8 mg and 6.0 mg did worse than 2.4 mg, which is why a quadratic was fitted; the likely reason is that 18 of 75 left the 6.0 mg arm during escalation and non completers counted as non responders. Quoting 62 percent alone presents the peak of that curve as the drug effect.
SYNCHRONIZE-MASLD does not fill that gap and does not show that survodutide treats MASH. It had no biopsy endpoint, 90.3 percent of participants lacked biopsy confirmed MASH, and liver stiffness by magnetic resonance elastography did not differ from placebo, p equals 0.6235. What does support a liver specific mechanism is a mediation analysis in 170 participants with paired biopsies, where only 36.3 percent of the fibrosis effect was mediated by weight loss.
The dose that is not the target dose
4.8 mg is not the target dose. It was a phase 2 arm and is a titration way-point in phase 3, which uses 3.6 and 6.0 mg in obesity and 6.0 mg in the liver trials. There is no label, so there is no established dosing, and any titration schedule circulating online did not come from a regulator.
Safety, including the correction that cuts the other way
Discontinuation for adverse events in phase 3 was roughly 24 percent at 3.6 mg and 25 percent at 6.0 mg against 5.4 percent placebo. Against the 2.6 to 7.1 percent range reported for approved agents in this class, that is three to nine times the rate, and it is the hardest single number against the compound. It stands, and it is usually quoted without its two qualifiers. Overall completion was effectively identical on drug and placebo in both programmes, 61 against 60 percent in phase 2 obesity and 41.1 against 40.0 percent discontinuing in SYNCHRONIZE-MASLD, so total attrition was not drug specific even though adverse event attrition was. And in the phase 2 obesity trial, where the breakdown was published, 74 percent of adverse event discontinuations, 56 of 76, happened during the 20 week rapid escalation phase, before anyone reached a maintenance dose. No equivalent breakdown has been published for either phase 3 trial.
Gastrointestinal adverse events in SYNCHRONIZE-1 reached 80.9 percent at 3.6 mg and 89.7 percent at 6.0 mg against 47.9 percent placebo. Serious adverse events were not increased, 8 against 7 percent in the phase 2 MASH trial. Heart rate rose 3.6 beats per minute against 0.8 at week 52 in SYNCHRONIZE-MASLD, and about 3.2 to 3.5 beats per minute at week 76 in SYNCHRONIZE-1. No deaths were reported.
Regulatory status
Survodutide is not approved by any regulator anywhere, for any indication, and no marketing application has been filed anywhere. Every expedited designation it holds is a liver pathway. The FDA granted Breakthrough Therapy designation on 8 October 2024, verbatim, for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis (stages 2 or 3). It also holds FDA Fast Track, EMA PRIME, and breakthrough designations in China and Taiwan. Nothing covers obesity.
The 2024 to 2025 picture of a phase 2 asset with a liver signal is stale. SYNCHRONIZE-1 published in the New England Journal of Medicine and SYNCHRONIZE-MASLD in Nature Medicine, both June 2026. SYNCHRONIZE-2 has not reported and is scheduled for the EASD meeting in Milan, eleven days from the date on this page. SYNCHRONIZE-CVOT, 5,531 participants, completed on 1 June 2026 with no public results. LIVERAGE runs to December 2031.
A dated list of what is expected next for survodutide, with the source for each date, is on its card on the Weight Loss Atlas pipeline tracker.
What circulates, and why no numbers appear here
Survodutide is sold online as lyophilised powder in milligram labelled vials under research use framing, with titration charts, reconstitution guides and projected approval timelines presented as though a regulatory process were under way. None of it comes from a regulator.
This site does not reproduce the circulating figures for survodutide, because the compound is unapproved, the escalation is where the harm sits, and material sold under this name has no established relationship between what the label says and what the vial contains. In the trials, escalation ran 20 to 24 weeks with four weekly clinical contact and permitted dose reduction, and a quarter of participants left anyway. A web page table is not that.
What the record gets wrong
One aggregator page is the origin of most of the structural and pharmacokinetic errors in circulation. It places the modifications at positions 18, 20 and 23, where the documented sites are position 2, position 24 and the C terminus. It gives survodutide GLP-1 receptor potency as 20 pM and glucagon potency as 108 pM against native GLP-1 at 5 pM, where the primary source gives 0.33 nM, 0.52 nM and 60 pM; its 20 pM is in fact the Zimmermann figure for native glucagon. It gives a human half life of 109 to 115 hours, uncited, and no human terminal half life could be sourced to a primary publication for this entry, so none is stated here. It also dates the Breakthrough Therapy designation to September 2024.
The question nobody is asking
In SYNCHRONIZE-1, going from 3.6 mg to 6.0 mg bought 0.8 percentage points of weight loss, minus 12.2 against minus 13.0 percent, with responder rates effectively identical at 72.6 and 71.9 percent. Over the same step, gastrointestinal adverse events rose from 80.9 to 89.7 percent and gastrointestinal discontinuation from 17.8 to 20.2 percent. And 6.0 mg is the dose carried into LIVERAGE, the trial that has to prove the liver indication, even though 4.8 mg outperformed it on phase 2 histology. Whether 6.0 mg is the right dose for either indication is the sharpest open question about this compound, and no published source addresses it.
Frequently asked questions
What is survodutide?
An investigational, once-weekly injectable peptide built on the glucagon hormone rather than GLP-1, engineered to activate both the glucagon and GLP-1 receptors together. It is not approved anywhere.
How does it work?
It combines two mechanisms: GLP-1 receptor activation to suppress appetite, and glucagon receptor activation, which in animal studies raises energy expenditure without necessarily reducing food intake further. Whether the energy-expenditure part actually works in humans has not yet been directly measured.
What dosage has been studied?
Phase 3 obesity trials dose-adjust patients up to 3.6 mg or 6.0 mg once weekly. Liver-disease trials use up to 6.0 mg once weekly. Earlier phase 2 trials tested a wider range down to 0.6 mg. There is no approved or established dose.
Why do some sources quote 16 to 19 percent weight loss and others 12 to 13 percent?
The higher figures are secondary, “efficacy estimand” analyses that assume perfect adherence and exclude anyone who stopped early or used other weight medication. The trial’s prespecified primary result, which counts everyone as randomised, is 12.2 to 13.0 percent at 76 weeks.
What dosage commonly circulates online?
This site does not reproduce circulating dosage figures for survodutide. It is unapproved for every use, sold research-use-only material carries no assurance of content or purity, and titration schedules circulating online do not come from a regulator.
Has it been studied in humans?
Yes, extensively, across phase 2 and phase 3 trials in obesity, type 2 diabetes and liver disease (MASH), plus a large cardiovascular outcomes trial that completed in mid-2026 with results not yet public.
What side effects have been reported?
Mostly gastrointestinal, affecting up to about 90 percent of participants at the higher dose. Discontinuation due to side effects ran roughly 24 to 25 percent in phase 3 trials, three to nine times the rate reported for approved drugs in this class, though total study dropout was similar between drug and placebo groups.
Is it approved anywhere?
No. It holds FDA Breakthrough Therapy and Fast Track designations, plus similar expedited pathways in Europe, China and Taiwan, all specific to liver disease. No marketing application has been filed anywhere for any use.
What remains unknown?
Whether it actually raises energy expenditure in humans, whether the liver benefit holds up with biopsy-confirmed endpoints in phase 3, full cardiovascular safety, what happens after stopping treatment, and how it compares head-to-head with approved drugs like tirzepatide.
Bottom line
Survodutide is a genuinely different mechanism from single-target GLP-1 drugs, built on glucagon rather than GLP-1, with a real weight-loss effect and a promising, FDA-fast-tracked liver-disease signal. But nearly every dramatic number attached to it in casual conversation, 16 to 19 percent weight loss, an 83 percent liver response rate, comes from a secondary analysis rather than the trial’s actual primary result, which is meaningfully smaller in every case. Its side-effect discontinuation rate in phase 3 trials is several times that of approved drugs in its class. It is not approved anywhere, its central proposed mechanism (added energy expenditure) has never been directly measured in a human being, and its cardiovascular outcomes trial has completed without public results.
Related entries: retatrutide, the GIP, GLP-1 and glucagon triple agonist; mazdutide, a GLP-1 and glucagon dual agonist.
Sources
- Ji L, Chen L, Cheng Z, Lu Y, Yang Y, Fu F, Zhu Y, Jin L, Kloer IM. Survodutide for obesity in Chinese adults: phase 3 randomized trial design and baseline characteristics (SYNCHRONIZE-CN). Diabetes Ther. 2026. Human phase 3, n=306 Chinese adults randomised 1:1:1 to once weekly subcutaneous survodutide 3.6 mg, survodutide 4.8 mg or placebo over 76 weeks. Source for SYNCHRONIZE-CN being the only phase 3 in the programme carrying a 4.8 mg arm and the only one whose primary endpoints, percentage change in body weight and achievement of at least 5 percent weight reduction, are read at week 52. PMID 42599381
- Survodutide Once Weekly for the Treatment of Adults with Obesity. N Engl J Med, 7 June 2026. NCT06066515. Human phase 3, n=725, 76 weeks, doses adjusted up to 3.6 or 6.0 mg. The source of record for the primary treatment regimen estimand figures of minus 12.2, minus 13.0 and minus 5.4 percent, and therefore for the fact that 16.6 percent is not the primary analysis. PMID 42253238
- Kaplan LM, et al. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med, 7 June 2026. NCT06309992. Human phase 3, n=216 treated, 6.0 mg, 48 weeks. Establishes both estimand figures, the absence of any MRE liver stiffness difference, and the eight-fold GLP-1 receptor bias statement. PMID 42252333
- Author Correction: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease. Nat Med, 25 August 2026. Human. No abstract is indexed, so the corrected items could not be established; it should be read before any SYNCHRONIZE-MASLD figure is republished. PMID 42642663
- Sanyal AJ, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. 2024;391(4):311-319. NCT04771273. Human, n=293 treated, 48 weeks. MASH improvement in 47, 62 and 43 percent against 14 percent placebo on a quadratic dose response; fibrosis improvement in 34, 36 and 34 percent against 22 percent with no significance claimed. PMID 38847460
- le Roux CW, et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024;12(3):162-173. NCT04667377. Human, 386 treated, 46 weeks. The source of record for the planned treatment figures of minus 6.2 to minus 14.9 percent and for 60.4 percent completion. PMID 38330987
- Bluher M, et al. Dose-response effects on HbA1c and bodyweight reduction of survodutide compared with placebo and open-label semaglutide in people with type 2 diabetes. Diabetologia. 2024;67(3):470-482. NCT04153929. Human, n=413, 16 weeks. HbA1c fell up to 18.72 mmol/mol, 1.71 percent, which is the human resolution of the glucagon paradox. PMID 38095657
- Zimmermann T, et al. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Mol Metab. 2022;66:101633. Preclinical. Establishes the 29 amino acid glucagon derived structure, Ac4c at position 2, the position 24 glycine serine linker with C18 diacid, C terminal amidation, the CHO-K1 and 100 percent plasma potencies, and the glucose comparison against a glucagon only agonist. PMID 36356832
- Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation. Mol Metab. 2026;105:102326. Preclinical, human and mouse tissue plus mouse in vivo. The definitive source for the glucagon receptor being barely detectable in the area postrema and arcuate nucleus, and for a long acting glucagon receptor agonist reducing body weight without reducing food intake. PMID 41638399
- The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection. Diabetes Obes Metab. 2024;26(6):2368-2378. Preclinical. Establishes that survodutide was selected from 19 dual agonists alongside BI 456908 and BI 456897. PMID 38560764
- Jungnik A, et al. Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906. Diabetes Obes Metab. 2023;25(4):1011-1023. NCT03175211, NCT03591718. Human, 24 and 125 participants. Placebo corrected weight loss of 13.8 percent at week 16, and falls in plasma amino acids and glucagon as dual target engagement. PMID 36527386
- Subgroup analysis by sex and baseline BMI in the phase 2 trial of survodutide. Diabetes Obes Metab. 2025;27(4):1773-1782. NCT04667377. Human. The source for adverse event discontinuation of about 25 percent on pooled survodutide and for the statement that 74 percent, 56 of 76, of those discontinuations occurred during the 20 week rapid escalation. PMID 39821928
- Weight reduction-dependent and independent effects of survodutide on liver endpoints: mediation analysis of a phase 2 trial in MASH. Hepatology, 3 August 2026. NCT04771273. Human post hoc in 170 participants with paired biopsies. Only 36.3 percent of the fibrosis effect was mediated by weight reduction. PMID 42545725
- Lawitz EJ, et al. Efficacy, tolerability and pharmacokinetics of survodutide in cirrhosis. J Hepatol. 2024;81(5):837-846. NCT05296733. Human phase 1, open label, n=41 in the multiple dose part. The documented source for escalation from 0.3 mg to 6.0 mg over 24 weeks, and for pharmacokinetic comparability across Child-Pugh classes. PMID 38857788
- Kushner PR, Michos ED. Cardiovascular Effects of Glucagon Receptor Signaling Alone and Combined With GLP-1 Receptor Signaling in Multiagonists. J Am Heart Assoc. 2026;15(15):e049727. Narrative review. Establishes that human cardiac glucagon receptor expression is not unequivocally demonstrated, that high dose glucagon is chronotropic and hypertensive, and that at least one other dual agonist was discontinued over heart rate and QT. PMID 42535526
- Boehringer Ingelheim. Cardiovascular outcomes trial of survodutide, 5,531 randomised, adjudicated five point MACE primary endpoint tested for non-inferiority. Completed 1 June 2026. No results posted and no publication located. NCT06077864
- Boehringer Ingelheim. Phase 3 trial in non-cirrhotic MASH with F2 to F3 fibrosis, approximately 1,800 adults, maximum 6 mg weekly. Co-primary endpoints in part one are MASH resolution and at least one stage fibrosis improvement. Recruiting, primary completion 27 December 2031. NCT06632444
- Boehringer Ingelheim. Open label study of the effect of survodutide on energy expenditure and fatty acid oxidation against semaglutide in 64 people with obesity. Active, not recruiting; primary completion 8 January 2027. The trial that will first measure in humans the mechanism the compound is marketed on. NCT06745284
- Boehringer Ingelheim and Zealand Pharma announcement, 8 October 2024, of FDA Breakthrough Therapy designation for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis and moderate or advanced fibrosis, stages 2 or 3, together with the initiation of LIVERAGE and LIVERAGE-Cirrhosis. Not peer reviewed, and independently reported the same day. Sponsor announcement, 8 October 2024
Live registry status
These are the registered trials this page cites, pulled from ClinicalTrials.gov and refreshed automatically. Status and dates are what the registry currently shows. Listing a trial here does not mean it produced a positive result.
Compare Survodutide with related compounds
Research area: Metabolic and incretin.